PMID- 19276559
OWN - NLM
STAT- MEDLINE
DCOM- 20090518
LR  - 20101022
IS  - 1387-2877 (Print)
IS  - 1387-2877 (Linking)
VI  - 16
IP  - 3
DP  - 2009
TI  - Increase of BDNF serum concentration in lithium treated patients with early 
      Alzheimer's disease.
PG  - 649-56
LID - 10.3233/JAD-2009-1004 [doi]
AB  - Preclinical and clinical studies gave evidence that lithium could be useful in 
      the treatment of Alzheimer's disease (AD). In experimental investigations, 
      lithium induces brain-derived neurotrophic factor (BDNF). Recent studies have 
      found a decrease of BDNF in the serum and brains of AD patients with potentially 
      consecutive lack of neurotrophic support. We assessed the influence of a lithium 
      treatment on BDNF serum concentration in a subset of a greater sample recruited 
      for a randomized, single-blinded, placebo-controlled, parallel-group multicenter 
      10-week study, investigating the efficacy of lithium treatment in AD patients. In 
      AD patients treated with lithium, a significant increase of BDNF serum levels, 
      and additionally a significant decrease of ADAS-Cog sum scores in comparison to 
      placebo-treated patients, were found. Diminution of cognitive impairment was 
      inversely correlated with lithium serum concentration. Upregulation of BDNF might 
      be part of a neuroprotective effect of lithium in AD patients. The results of the 
      present investigation encourage performing studies with longer treatment phases 
      to observe potential positive long-term effects of lithium in AD patients.
FAU - Leyhe, Thomas
AU  - Leyhe T
AD  - Department of Psychiatry and Psychotherapy, University of Tubingen, Tubingen, 
      Germany. thomas.leyhe@med.uni-tuebingen.de
FAU - Eschweiler, Gerhard W
AU  - Eschweiler GW
FAU - Stransky, Elke
AU  - Stransky E
FAU - Gasser, Thomas
AU  - Gasser T
FAU - Annas, Peter
AU  - Annas P
FAU - Basun, Hans
AU  - Basun H
FAU - Laske, Christoph
AU  - Laske C
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Lithium Compounds)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Placebos)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*blood/*drug therapy
MH  - Antipsychotic Agents/*administration & dosage
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Cognition Disorders/blood/drug therapy
MH  - Female
MH  - Humans
MH  - Lithium Compounds/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Neuroprotective Agents/blood
MH  - Placebos
MH  - Severity of Illness Index
EDAT- 2009/03/12 09:00
MHDA- 2009/05/19 09:00
CRDT- 2009/03/12 09:00
PHST- 2009/03/12 09:00 [entrez]
PHST- 2009/03/12 09:00 [pubmed]
PHST- 2009/05/19 09:00 [medline]
AID - 54625016X535L411 [pii]
AID - 10.3233/JAD-2009-1004 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2009;16(3):649-56. doi: 10.3233/JAD-2009-1004.